Previous 10 | Next 10 |
$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2 2024 Presented positive data from Phase 1b EQUALISE study of itolizumab in lupus nephr...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Mic...
2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...
2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 30.8% to $21.87 on volume of 421,271,485 shares InVivo Therapeutics Holdings Corp. (NVIV) rose 136.9% to $0.526 on volume of 188,439,590 shares New York Community Bancorp Inc. (NYCB) fell...
EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024 EQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of further clinical development of EQ102 based on EQ302’s optimal delivery and increase...
EQ Bank Card launches in Québec as Carte Banque EQ Canada NewsWire Popular bank card gives customers the ability to earn, save, and spend their money TORONTO , Nov. 20, 2023 /CNW/ - EQ Bank (Banque EQ in Québec) is offering Québec customers...
Revenue Increases Over 24% Year Over Year - Adjusted EBITDA on Track to Profitability TORONTO, ON / ACCESSWIRE / November 16, 2023 / EQ Inc. (TSXV:EQ) ("EQ", "EQ Works" or the "Company"), a leader in AI and geospatial data driven software and solutions, announced its financial results today ...
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...
Equillium Inc. (EQ) is expected to report $-0.16 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...